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Introduction: Lung cancer is often diagnosed by cytology, neces-
sitating predictive molecular marker analyses on cytological speci-
mens. The gold standard for detection of predictive anaplastic 
lymphoma kinase (ALK)-rearrangements is fluorescence in situ 
hybridization (FISH), but FISH is both expensive and often challeng-
ing to interpret. The aim of our study was to investigate the accuracy 
of ALK immunocytochemistry (ICC) on cytological specimens of 
non–small-cell lung cancers (NSCLCs).
Methods: Forty-one cytological specimens with available ALK 
FISH results were retrospectively analyzed with the 5A4 monoclo-
nal antibody (Novocastra; Leica Biosystems) on a fully automated 
slide stainer. The specimens were enriched for ALK FISH-positive 
NSCLCs (14 of 41; 34.1%). Evaluation of the ICC staining was per-
formed blinded to the FISH results. The staining intensity and the 
percentage of stained cancer cells were recorded. Any ICC staining 
was regarded as a positive result. The ALK ICC results were com-
pared with the FISH results. In case of a discrepancy the ICC-stained 
slide and the FISH signals were reviewed.
Results: ICC was evaluable on 40 of 41 specimens. Fifteen of 40 
NSCLCs (37.5%) were ALK ICC-positive, with staining of the 
majority of cancer cells (median 100%; mean 82.3%). Twelve of 
the ICC-positive NSCLCs (80.0%) showed an intense staining (3+). 
Compared with the ALK FISH results, only one NSCLC was false-
negative, and one false-positive by ICC, respectively. The sensitivity, 
specificity, and positive and negative predictive values for ALK ICC 
compared with ALK FISH were 93.3%, 96.0%, 93.3%, and 96%, 
respectively.
Conclusion: ALK ICC is highly accurate for detecting ALK-
rearranged NSCLCs.
Key Words: Anaplastic lymphoma kinase, Lung cancer, Cytology, 
Immunocytochemistry, Fluoresence in situ hybridization.
(J Thorac Oncol. 2013;8: 1004-1011)
The discovery of targetable oncogenic driver mutations, like in epidermal growth factor receptor (EGFR), and more 
recently in anaplastic lymphoma kinase (ALK), has revolu-
tionized diagnosis and treatment of advanced-stage non–
small-cell lung cancers (NSCLCs), which is the leading cause 
of cancer-related mortality, worldwide.1–3
ALK was first discovered in anaplastic large-cell lym-
phomas (ALCLs) when the ALK-nucleophosmin fusion was 
identified.4 ALK-rearrangements as a driver mutation in 
NSCLCs were discovered in 2007 by the identification of the 
oncogenic echinoderm microtubule-associated protein-like 
4 (EML4)-ALK fusion transcript.5,6 ALK is a receptor tyro-
sine kinase and is inactive in its native form. ALK rearrange-
ments lead to a ligand-independent, constitutive ALK receptor 
tyrosine kinase activity engaging major signaling pathways 
responsible for tumor growth and antiapoptosis.7 EML4-ALK 
results from a small inversion within the short arm of chromo-
some 2 involving 2p21 and 2p23. The breakpoint of ALK is 
nearly always located at exon 20, with various breakpoints in 
the amino terminal of EML4, leading to different EML4-ALK 
isoforms. Since the EML4-ALK discovery, at least 27 differ-
ent ALK fusion variants have been described, mostly com-
prising different EML4-ALK isoforms and rarely because of 
other fusion partners like KIF5B, KLC1, and TFG.8
Only 4 years after the discovery of EML4-ALK in 
NSCLC, crizotinib, a dual ALK-MET inhibitor, has been 
approved by the Food and Drug Administration (FDA) in the 
United States for the treatment of advanced-stage NSCLCs, 
harboring ALK-rearrangements. The success of a targeted 
drug is critically dependent on a sensitive and specific 
screening assay to detect the molecular drug target.1,9 The 
gold standard for detection of predictive ALK rearrangements 
is currently break-apart fluorescence in situ hybridization 
(FISH), as it is able to detect all known ALK-rearrangements 
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and was clinically validated in crizotinib clinical trials.2 But 
FISH is both expensive and complex in its interpretation and 
not available in every laboratory.10 Detection of ALK fusion 
protein expression by immunocytochemistry (ICC) would 
have several advantages over FISH in terms of availability, 
turnaround time, and costs. Compared with ALK-positive 
ALCLs, ALK-rearranged NSCLCs show a relatively low level 
of ALK fusion protein expression. Standard ICC protocols, 
well established in ALCL diagnosis, are therefore, not 
sensitive enough to detect all ALK-rearranged NSCLCs.11,12 
Recently, new promising antibodies and highly sensitive ICC 
protocols have been developed, and ALK ICC with the 5A4 
monoclonal antibody (mAb) (Novocastra; Leica Biosystems, 
Newcastle Upon Tyne, United Kingdom) has been proposed 
for prescreening adenocarcinomas (ADCs) on histological 
specimens.13,14 Approximately 70% of NSCLCs are diagnosed 
in an advanced, inoperable stage of disease, often by cytology, 
making it necessary to perform predictive marker analyses 
on cytological specimens.15,16 The aim of our study was 
to investigate the feasibility and accuracy of ALK ICC on 
cytological specimens of NSCLCs.
PATIENTS AND METHODS
Patient’s Selection and Cytological Specimens
Forty-one NSCLCs from patients with advanced-stage 
disease, known ALK FISH status, and an adequate amount of 
cancer cells for ICC on conventional cytology smears (n = 38), 
cytospins (n = 2), and one liquid-based preparation were 
retrospectively included in the study. The study population 
was enriched for consecutive ALK FISH-positive NSCLCs 
(n = 14; 34.1%). Eighteen consecutive ALK FISH-negative 
NSCLCs with EGFR and KRAS wild-type were included as 
negative controls. Because ALK rearrangements are practi-
cally mutually exclusive to other known driver mutations, nine 
consecutive NSCLCs with EGFR (n = 4), KRAS (n = 4), or 
BRAF (n = 1) mutations were also analyzed by ALK FISH 
and included as negative controls.
ALK FISH analyses were performed, except for the 
EGFR, KRAS, or BRAF-mutated NSCLCs, prospectively 
in the diagnostic setting from September 2009 to August 
2012. In nine of 41cytological specimens, matched forma-
lin-fixed and paraffin-embedded (FFPE) cytological mate-
rial were available as cellblocks, which were also analyzed 
by ALK ICC.
Cytological specimens were retrieved from the archives 
of the Institute of Pathology, University Hospital, Basel 
(n = 21), the Institute of Surgical Pathology, University 
Hospital, Zurich (n = 8), and the Cantonal Hospitals Lucerne 
(n = 7) and Winterthur (n = 5). They included specimens from 
pleural and pericardial effusions (n = 20 and n = 1, respec-
tively), fine-needle aspirations of lymph nodes and the lung 
(n = 11 and n = 6, respectively), two bronchial secretions, and 
one bronchial brushing.
Cytology smears were processed according to rou-
tine procedures, using Delaunay solution as a fixative, and 
evaluated by experienced cytopathologists. Cellblocks were 
prepared using the plasma-thrombin method.17
ALK Immunocytochemistry
ICC was performed directly on cytology speci-
mens fixed in Delaunay solution and stained according to 
Papanicolaou. After uncovering the glass slides, the ICC 
reaction was performed using the automated immunos-
tainer Bond-Max according to the manufacturer’s recom-
mendations with minor modifications (Leica Microsystems, 
Wetzlar, Germany). In brief, the slides were pretreated in 
Epitope Retrieval Solution 2 for 5 minutes at 100°C and then 
incubated with the mouse mAb for ALK (dilution 1:50) for 
30 minutes at room temperature (Novocastra; Clone 5A4, 
Leica Biosystems). Antibody binding was detected using 
the Bond Polymer Refine Detection Kit, which enhances 
cell penetration and detection sensitivity through small mul-
tifunctional linkers, with 3,3′-diaminobenzidine as chromo-
gen (Leica Microsystems).
FFPE cellblocks were sectioned at 4-μm thickness and 
processed same as cytology smears, except for an additional 
deparaffinization step, a longer pretreatment (30 minutes) and 
a higher antibody concentration (dilution 1:10), with a shorter 
incubation (15 minutes).
Cytospins and cellblock sections of an ALK-rearranged 
and FISH-validated cell line (H3122) were used as positive 
controls, respectively. The evaluation of the ICC staining was 
performed blinded to the FISH results. The staining intensity 
was scored as previously described: 0, no staining; 1, faint 
cytoplasmic staining; 2, moderate cytoplasmic staining; and 
3, strong cytoplasmic staining, and the percentage of stained 
cancer cells was recorded.18,19 Any ICC staining was regarded 
as a positive ALK ICC result. Every ICC-stained slide was 
independently scored by two cytopathologists (L.B. and S.S.). 
In case of a discrepant ICC result between the two observ-
ers, the slides were reviewed and a consensus was reached. 
The ALK ICC results were compared with the FISH results. 
In case of a discrepancy the ICC-stained specimens and the 
FISH signals were reviewed.
ALK Fluorescence In Situ Hybridization
The majority of diagnostic ALK FISH analyses of the 
study population (32 of 41; 78%) were performed on cytological 
specimens fixed in Delaunay solution and stained according to 
Papanicolaou. On cytology smears with only sparse cancer cells 
and strong intermixture with benign cells, the exact locations 
of the cancer cells were saved by a relocation software (Metafer 
4, version 3.3.110; MetaSystems, Baden-Württemberg, 
Germany) and an automated stage (Märzhäuser, Wetzlar, 
Germany) on an epifluorescence microscope (Axioplan 2 
Imaging; Zeiss, Oberkochen, Germany). Before uncovering 
and hybridization, the cancer cells were photographed with 
a digital camera (AxioCam; Zeiss, Göttingen, Germany), and 
the target area was permanently marked on the slide with a 
diamond pen. FISH was then performed using a commercially 
available ALK probe (Vysis LSI ALK dual-color, break-apart 
rearrangement probe; Abbott Molecular, Abbott Park, IL). 
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Our detailed cytology ALK FISH protocol has recently been 
published.20 FISH on FFPE biopsies (9 of 41) was performed 
on 4-μm-thick tissue sections according to the manufacturer’s 
recommendations.
FISH scoring on cytological specimens was done by 
cytotechnicians experienced in FISH analyses, and the results 
were reviewed by a cytopathologist (L.B. or S.S.). FISH scor-
ing on biopsies was done by technicians experienced in FISH 
analyses, and the results were reviewed by a pathologist. The 
FISH signals were analyzed on a z-stacked two-dimensional 
picture. Fifty cancer cells per case were scored and evaluated 
according to the manufacturers recommendations, which were 
based on a study by Camidge et al.10
A cancer cell is defined to be positive for ALK rear-
rangement if (1) a split signal (single red and single green 
signal with a signal-separation distance of at least two signal 
diameters), or (2) a single red signal without a corresponding 
green signal is present.
A lung cancer is defined as being ALK FISH-negative if 
less than 10% of cancer cells are positive for ALK rearrange-
ments, and as being ALK FISH-positive if more than 50% of 
cancer cells are positive for ALK rearrangements. In case of 
a borderline result with 10% to 50% ALK-rearranged cancer 
cells, the evaluation was repeated by a second independent 
scorer. A mean of both independent evaluations of at least 
15% is defined as FISH-positive result. Inflammatory cells 
served as internal control and had two fused or adjacent red/
green signals with a signal-separation distance of less than 
two signal diameters.
Data Analysis
Interobserver agreement for ALK ICC results per-
formed by two pathologists (L.B and S.S) was measured with 
the Cohen’s κ coefficient and interpreted according to Landis 
and Koch.21 Contingency table analysis was used to assess 
the association between ALK ICC-staining intensity and 
ALK FISH results. Associations between categorical vari-
ables were performed using Fisher’s exact test (two-sided). 
Differences in the mean age of patients with ALK FISH-
positive and ALK FISH-negative lung carcinomas were 
evaluated using Student’s t test. Sensitivity, specificity, and 
positive and negative predictive values of ALK ICC and ALK 
FISH for predicting the final ALK status were calculated. p 
TABLE 1.  Correlation between ALK ICC-Staining Intensity 
and the Final ALK FISH Results
ICC-Staining Intensity
FISH
TotalPositive (%) Negative (%)
0 1 (6.7) 24 (96.0) 25
1+ 0 1 (4.0) 1
2+ 2 (13.3) 0 2
3+ 12 (80) 0 12
Total 15 25 40
ICC, immunocytochemistry; FISH, fluorescence in situ hybridization.
FIGURE 1.  Nonspecific staining in ALK ICC. 
A–C, Non-neoplastic cells: Macrophages (A, 
original magnification: 600×), squamous 
epithelial cells (B, original magnification: 
600×), and leucocytes (C, original magnifica-
tion: 600×). The cancer cells are negative for 
ALK ICC (arrows). D, Unspecific background 
staining in the central portion of three-
dimensional tissue fragments. The cancer 
cells in the periphery of the tissue fragment 
and in the background are negative for ALK 
ICC (original magnification: 600×). ICC, 
immunocytochemistry; ALK, anaplastic lym-
phoma kinase.
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values less than 0.05 were considered statistically significant. 
All analyses were performed with JMP 10 software (SAS 
Institute, Cary, NC).
This study was in accordance with the local institutional 
review board in Basel, Switzerland.
RESULTS
ALK Immunocytochemistry
ALK ICC was evaluable on 40 of 41 cytological speci-
mens because one FISH-positive NSCLC lacked cancer cells 
after uncovering and ICC. Fifteen of 40 NSCLCs (37.5%) 
showed an ALK ICC-positive result (Table 1). A nonspe-
cific, faint-to-moderate staining of non-neoplastic cells was 
observed in two of 40 specimens (5%), including macrophages 
and squamous epithelial cells in a bronchial secretion of one 
specimen, and leucocytes in a pleural effusion of another one 
(Fig. 1A-C). In addition, five of 40 specimens (12.5%) had 
weak-to-moderate nonspecific background staining in the 
central portion of the three-dimensional cell clusters or tissue 
fragments (Fig. 1D). The interobserver agreement was excel-
lent with a κ value of 0.83 (95% confidence interval 0.66–
1.01). In three cases, the ICC results were discordant between 
the two cytopathologists. All these specimens were scored as 
negative by the first, and as 1+ positive by the second observer, 
respectively. The consensus of the ICC result was negative in 
two cases, which showed unspecific background staining. The 
remaining case was scored as ALK ICC 1+ positive.
ALK Fluorescence In Situ Hybridization
ALK FISH was evaluable in all cases by design and per-
formed on cytological specimens in 32 of 41 (78%) and on 
FFPE tissue sections in 9 of 41 (22%) of all NSCLC. In ALK 
FISH-negative NSCLCs (n = 25), the mean percentage of can-
cer cells with positive FISH signals on cytology (n = 19) and 
FFPE tissue specimens (n = 6) was 3.4% and 2.8%, respec-
tively (median 4%; range, 0–13% and median 4%; range, 
0–6%, respectively). On ALK FISH-positive NSCLCs, the 
mean percentage of cancer cells with positive FISH signals 
on cytological specimens (n = 13) was 60.3% (median 63%; 
range, 18–100%). In four of these ALK-rearranged NSCLCs 
on cytology, the percentage of cancer cells with positive FISH 
signals was less than 50% (18%, 22%, 22%, and 27%, respec-
tively). The three ALK-rearranged NSCLCs analyzed on 
FFPE tissue sections showed 27%, 70%, and 92% of cancer 
cells with positive FISH signals, respectively.
Correlation between ALK ICC 
and ALK FISH Results
There were four discrepant results between the ALK 
ICC and the original ALK FISH analyses: One carcinoma had 
a negative ALK ICC, with a positive FISH result, and three 
had positive ALK ICC but negative FISH results. The ICC-
stained slides and FISH signals of these four carcinomas were 
reviewed. The FISH of the ICC-negative carcinoma showed 
split signals in only 22% of cancer cells, but clearly fulfilled 
the criteria for being FISH-positive (Fig. 2A, B). Two of the 
three FISH-negative but ICC-positive carcinomas had a strong 
staining (3+) in 100% of cancer cells (Fig. 3A, C). A review of 
these FISH with strong ICC staining revealed FISH-positive 
results with single red signals in 88% and split signals in 50% 
of cancer cells, respectively (Fig. 3B, D). In fact, the origi-
nal FISH results of these two carcinomas were false-negative. 
The false-negative FISH result with detection of single red 
signals in the re-evaluation resulted from misinterpretation 
of these signals as artefacts in the original evaluation. The 
false-negative FISH result with detection of split signals in 
the re-evaluation was because of misinterpretation of benign 
cells as carcinoma cells on a cell block of a pleural effusion. 
This initial FISH evaluation had been performed by a tech-
nician and pathologist without experience in cytopathology. 
The third ALK ICC-positive carcinoma with a FISH-negative 
result showed a faint staining intensity (1+) in 80% of cancer 
cells, with a clearly negative FISH result without the presence 
of any ALK-rearranged signals (Fig. 3E, F).
One might suspect that a small proportion of ALK 
FISH-positive cells in ALK-rearranged lung cancers represent 
intratumoral heterogeneity. In fact, the NSCLCs with lowest 
percentage of cells with ALK-positive FISH signals in cytology 
(18%) revealed strong (3+) but only very focal ICC-positivity 
in one isolated carcinoma cell group (2% of all carcinoma 
cells). In contrast, the NSCLC with 27% positive FISH signals 
was diffusely ICC 3+ positive in all carcinoma cells. Similarly, 
the FISH-positive NSCLC analyzed on FFPE biopsy with 
27% FISH-positive signals was diffusely ICC 2+ positive. The 
evaluable NSCLC with 22% of positive FISH signals was ICC-
negative without ALK expression in any of the cancer cells.
The correlation between ALK ICC-staining intensity 
and the final FISH results is summarized in Table 1. Fifteen of 
FIGURE 2.  Adenocarcinoma with 
false-negative ALK immunocytochem-
istry and positive fluorescence in situ 
hybridization on the cytological smear 
of a lymph node fine-needle aspiration. 
No ALK immunostaining (A, original 
magnification: 200×) with a mean of 
22% break-apart signals (arrows) (B, 
original magnification: 1000×). ALK, 
anaplastic lymphoma kinase.
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40 NSCLCs (37.5%) were ICC-positive with staining of the 
majority of cancer cells (median 100%; mean 82.3%; range, 
3%–100%). As discussed above, there was only one carcinoma 
with weak ICC-staining intensity, which had a FISH-negative 
result (Fig. 2E, F). All the remaining ICC-positive carcinomas 
were FISH-positive. Twelve of 15 ICC-positive ADC (80.0%) 
showed a strong staining intensity (3+).
Clinicopathological characteristics and ALK ICC 
results of the ALK FISH-positive and negative lung carcino-
mas are summarized in Table 2. ALK FISH-positive carcino-
mas were significantly more common in female patients (p = 
0.02) and were all ADCs, except one case with adenosqua-
mous cytology. As all patients had advanced-stage disease, 
no tumor resections were performed, and therefore, a detailed 
histologic characterization of these ALK FISH-positive ADCs 
was not possible. There was no ADC with signet-ring cell 
morphology or much mucin secretion by cytology, features 
described in ALK FISH-positive ADC.11 However, one ALK 
FISH-positive ADC showed signet-ring cell morphology on a 
previous biopsy of a bone metastasis.
The median age was 3.5 months younger in ALK FISH-
positive than in ALK FISH-negative carcinomas, although 
this age difference was not statistically significant (p = 0.18).
The sensitivity, specificity, and positive and negative 
predictive values for ALK ICC compared with the final ALK 
FISH results are shown in Table 3.
All nine cytological specimens from carcinomas with 
EGFR (n = 4), KRAS (n = 4), or BRAF (n = 1) mutations, 
which were analyzed by FISH and included as negative con-
trols, were ALK FISH- and ALK ICC-negative, respectively.
The ICC results of all nine carcinomas on cellblocks 
were concordant with the results on the matched conventional 
cytological specimens (five ALK ICC-negative and four ALK 
ICC-positive carcinomas, respectively). The ICC results of 
these nine cytological specimens were all concordant with the 
FISH results.
DISCUSSION
Cytology is essential in lung cancer diagnosis and the 
only tumor material for diagnosis and molecular marker anal-
yses in up to 44%.15,16 Nevertheless, there are no published 
data on the performance of ALK testing in NSCLC on con-
ventional cytological specimens.
FISH and ICC are well established methods for 
diagnostic, prognostic, and predictive marker analyses in 
clinical cytology, and cytological specimens are particularly 
well suitable for DNA based analyses.16,22–24 We established 
an ALK FISH protocol using the FDA-approved FISH assay 
(Abbott Molecular) and an ALK ICC protocol, with the 5A4 
mAb for conventional cytology specimens. The same FISH 
and ICC protocols used for FFPE tissue specimens can be 
used on cellblocks. However, not all cytological specimens 
provide enough material for additional cellblock preparation, 
and a conventional cytological specimen is necessary for an 
appropriate morphological diagnosis. A recent prospective 
study documented an ALK FISH failure rate of 19%, mostly 
because of hybridization failures, on diagnostic FFPE tumor 
tissues of 100 lung ADCs.14 In October 2011, our Institute 
at the University Hospital Basel introduced systematic 
ALK FISH testing on all advanced-stage EGFR and KRAS 
wild-type non-squamous NSCLC by reflex or by request of 
the treating oncologists, as recently recommended.20 Since 
then, 143 ALK FISH analyses on all types of cytological 
specimens were performed and no hybridization failures 
were encountered (data not shown). The prevalence of ALK 
rearrangements was 6.2%, which is in line with previous 
reports in western populations.14 The better performance of 
FISH on cytological specimens compared with FFPE tumor 
tissues can be explained by faster cell fixation and better DNA 
FIGURE 3. A–D, Two adenocarcinomas in which the positive 
ALK ICC detected an ALK rearrangement. The initial ALK FISH 
were misinterpreted as being negative. Strong cytoplasmic 
immunostaining (3+) in 100% of cancer cells (A, C, original 
magnification: 200×) on the cytological smears of the lung 
FNA and the pleural effusion, respectively. FISH at re-evalu-
ation with single red signals in 88% (B) and split signals in 
50% (D) of cancer cells, respectively (original magnification: 
1000×). E–F, Non–small-cell carcinoma with false positive ALK 
ICC and a FISH-negative result. Faint cytoplasmic immunos-
taining (1+) in 80% of cancer cells on the cytological smear 
of the lung FNA (E, original magnification: 200×) with fused 
FISH signals on the corresponding tumor biopsy (F, original 
magnification: 1000×). ALK, anaplastic lymphoma kinase; 
ICC, immunocytochemistry; FISH, fluorescence in situ hybrid-
ization; FNA, fine-needle aspiration.
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quality. Alcohol-fixed or air-dried cytological specimens also 
lack the cross-linking of the DNA caused by formaldehyde 
fixation. We therefore prefer cytological specimens rather 
than histological sections for ALK FISH analysis, whenever 
possible. However, the cutoff defining a NSCLC as positive 
for ALK rearrangement has been established on FFPE 
histological specimens, where a proportion of cell nuclei are 
truncated in contrast to cytological specimens.10 The mean 
percentages of ALK FISH-positive cancer cells on cytological 
specimens of ALK-rearranged and ALK wild-type NSCLCs 
investigated in our study population (60.3%, range, 18–100%, 
and 3.4%, range, 0–13%, respectively) are comparable with 
the percentages reported by Camidge et al.10 (56%, range, 18–
100%, and 6%, range, 3.5–9.5%, respectively) using the same 
FISH assay and evaluation criteria on histological specimens. 
This suggests that the optimal thresholds for a positive ALK 
status might not differ significantly between cytological slides 
and histological sections. However, further studies are needed 
to further investigate this issue.
Regardless of the specimen type, ALK break-apart 
FISH is challenging in its interpretation and requires a high 
level of experience. In addition, it is not available in every 
laboratory and expensive for large-scale screening.10,20 The 
widely used ALK1 antibody (Dako, Glostrup, Denmark) for 
the diagnosis of ALK-positive ALCLs has a low sensitivity 
for the detection of ALK-rearranged NSCLC, even when 
using protocols with amplification systems, and has presented 
with unspecific background staining.11,12 Recent studies have 
shown promising results with the commercially available 
5A4 mAb (Novocastra) in terms of sensitivity, specificity, 
and interpretation reproducibility on FFPE histological 
specimens.12–14 ICC with the 5A4 mAb uncovered two 
ALK-rearranged ADCs with false-negative FISH results on 
initial evaluation in our study, underlying the difficulty of 
ALK break-apart FISH evaluation. McLeer-Florin et al. and 
Paik et al. recently investigated the performance of ALK ICC 
compared with ALK FISH in FFPE NSCLC tissue, using the 
5A4 mAb on a Benchmark immunostainer (Ventana, Tucson, 
AZ) and the same FISH assay as in our study. Both studies had 
no false-negative ICC results, with 100% sensitivity of ICC 
for detecting ALK FISH-positive NSCLC (n = 21 and n = 28, 
respectively). The ADC with the false-negative ICC result in 
our study showed only 22% of FISH-positive cancer cells, 
with most break-apart signals having a separation distance 
of just two signal diameters (Fig. 1). This case highlights 
the existence of borderline FISH-positive cases even after 
repeated FISH evaluation by two independent scorers. 
EML4 is located very close to ALK, only approximately 
12 megabases apart, on the short arm of chromosome 2. 
Therefore, the split signals in ALK break-apart FISH caused 
by an intrachromosomal inversion are not very far apart. 
Deciding on a separation distance of two signal diameters, 
which defines a break-apart signal, remains subjective, and 
might be one reason for such borderline FISH findings. Such 
cases could be clarified by additional techniques like ICC or 
reverse-transcriptase polymerase chain reaction. The patient 
did not receive treatment with crizotinib, so it remains 
unknown if the borderline FISH positivity would have been 
predictive for response to treatment, despite a negative ICC 
result. Two ALK-rearranged NSCLCs with only 27% ALK 
FISH-positive cells showed diffuse and unequivocal ALK 
expression (staining intensity 2+ and 3+, respectively) in all 
cancer cells, supporting the homogenous presence of ALK-
rearrangements.10,14,25 The discrepancy of a low percentage of 
detectable ALK FISH-positive cancer cells, despite diffuse 
and homogeneous ALK expression, has been attributed to 
technical factors, such as nuclear truncation or hybridization 
artefacts.10 It can also be explained to some extent by the 
three-dimensional distribution of break-apart FISH signals 
in the cell nuclei and their projection to the horizontal plane, 
which accounts for the fact that only a fraction of break-
apart signals are discernible.10,26 A homogenous and strong 
ALK expression was also observed by McLeer-Florin et 
al.,14 who, similar to our study, used a modified ICC protocol 
with an amplification Kit (Ventana) and the same criteria 
for ALK positivity, including a staining intensity of 1+ as 
positive result. Nineteen of 21 ALK-rearranged ADCs 
(90.5%) in their study had a staining intensity of 3+, with a 
mean percentage of positive cancer cells at 80%. Our results 
are well in line with these findings with 14 of 15 ALK-
rearranged NSCLCs (93.3%) showing clearly visible staining 
TABLE 2.  Clinicopathological Characteristics and ALK ICC 
Results Grouped by the Final ALK FISH Result
Characteristics
ALK FISH
pPositive Negative
Age (yr), median (range) 61.5 (29–80) 65 (34–85) 0.18
Sex
  Male (%) 5 (31.3) 18 (72)
  Female (%) 11 (68.7) 7 (28) 0.002
 Total 16 25
NSCLC Subtype
 ADC (%) 15 (93.8) 20 (80)
 NSCLC, NOS (%) 3 (12)
 TTF1+ NSCLC (%) 2(8)
 AD/SCC (%) 1 (6.2)
 Total 16 25
ALK ICC
 Positive 14 (93.3) 1 (4)
 Negative 1 (6.7) 24 (96)
 Total 15a 25
aOne ALK FISH-positive carcinoma not evaluable by ICC.
AD/SCC, adenosquamous carcinoma; ADC, adenocarcinoma; ALK, anaplastic 
lymphoma kinase; ICC, immunocytochemistry; FISH, fluorescence in situ hybridization; 
NOS, not otherwise specified; NSCLC, non–small cell lung cancer.
TABLE 3.  Sensitivity, Specificity, PPV and NPV of ALK ICC  
for the Prediction of the Final ALK FISH Results
Sensitivity Specificity PPV NPV
ALK ICC (%) 93.3 96.0 93.3 96
ALK, anaplastic lymphoma kinase; ICC, immunocytochemistry; FISH, fluorescence 
in situ hybridization; PPV, positive predictive value; NPV, negative predictive value.
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intensities of 2+ and 3+ (n = 2 and n = 12, respectively), 
and a mean percentage of positive cancer cells at 82.3%. 
This clearly visible and diffuse staining pattern makes ALK 
ICC interpretation straightforward, which is mirrored by the 
excellent interobserver agreement as was also reported by 
Paik et al.13 In our study, only one NSCLC was 1+ positive by 
ICC but negative by FISH, probably representing unspecific 
ICC staining. This is in contrast with McLeer-Florin et al.14, 
who reported two 1+ ICC-positive ADCs, which were FISH 
positive. However, in the study by Paik et al.13 all 16 of 640 
NSCLCs, which were 1+ positive by ICC were ALK FISH-
negative, whereas, the NSCLCs which were 2+ positive by 
ICC, showed variable FISH results.
Despite the striking evidence that ALK rearrangements 
in NSCLC are mostly homogeneous, it cannot be excluded 
that rare cases with heterogeneous ALK status exist, as sug-
gested by our ADC with a low proportion of ALK FISH-
positive cells and very focal 3+ ALK expression by ICC. 
Further studies using automated relocation of focal areas with 
ICC-positive cells for ALK FISH analysis or combined chro-
mogenic in situ hybridization with ICC will help to elucidate 
this question in the future.
It is problematic to recommend generally applicable 
algorithms for further FISH testing depending on different 
levels of ICC intensities (e.g., negative, 1+, 2+ or 3+) for the 
time being, because the results of the individual studies depend 
highly on the applied antibodies, protocols, and technical plat-
forms. Therefore, internal validation of new ALK ICC assays 
at each individual site together with participation in external 
quality assessment programs is advisable. Nevertheless, our 
data, along with other published results, suggest that ALK 
ICC with the 5A4 mAb is a valuable screening method for the 
detection of ALK-rearranged NSCLC, particularly in cyto-
logical specimens using our protocol on the Leica Bond-Max 
immunostainer. Given the high sensitivity of almost 100%, 
it seems safe to omit FISH testing in ALK ICC-negative 
NSCLC, thus saving as many as 90% of all ALK FISH analy-
ses in NSCLC. Further studies are needed to clarify whether 
ALK FISH confirmation is avoidable in NSCLC with a mod-
erate (2+) or strong (3+) staining intensity. Simultaneous 
testing of NSCLC for EGFR/KRAS mutations and for ALK 
expression by ICC will significantly reduce turnaround time, 
in countries where crizotinib is approved for first-line treat-
ment, and costs, making most ALK FISH analyses performed 
today unnecessary.
Interestingly, a new ALK (D5F3) rabbit mAb assay 
(Ventana) has recently been launched as a companion diag-
nostic for detecting ALK protein for selecting patients for 
treatment with crizotinib in the European Union, coinciding 
with the conditional approval and availability of crizotinib 
in all European Union member states.27 This assay is bound 
to histological tissue sections and the Ventana BenchMark 
immunostainer. Its practical value in daily routine and on 
cytological sections remains to be determined.
In conclusion, cytological NSCLC specimens are well 
suited for ALK rearrangement testing. ALK ICC with the 5A4 
mAb (Novocastra) is feasible and highly accurate for the detec-
tion of ALK-rearranged NSCLC on conventional cytological 
specimens and cellblock preparations and can be used for pre-
screening NSCLCs. In addition, this study provides detailed 
ALK FISH data performed with the FDA-approved FISH 
assay (Abbott Molecular) on cytological specimens of ALK-
rearranged and ALK-wild-type NSCLC. Minimally invasive 
techniques, such as endobronchial ultrasound-guided trans-
bronchial needle aspiration and electromagnetic navigation 
bronchoscopy, will probably even enhance the role of cytol-
ogy in lung cancer diagnosis.28 Cytological specimens should, 
therefore, be included in clinical trials on targeted therapies 
for predictive markers analysis. Protocols for predictive tests 
should be established for both, FFPE biopsies and cytologi-
cal specimens. And in diagnostic routine, all available tumor 
material of a patient, that is, biopsy and cytology, should be 
reviewed to choose the best material for predictive marker 
analyses.
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